Axon Enterprise (NASDAQ:AXON) Posts Earnings Results, Misses Estimates By $0.46 EPS

Axon Enterprise (NASDAQ:AXON) issued its quarterly earnings results on Tuesday. The biotechnology company reported $1.17 EPS for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46), Briefing.com reports. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The firm had revenue of $710.64 million for the quarter, compared to analysts’ expectations of $704.83 million. During the same period in the prior year, the company earned $1.45 EPS. The firm’s quarterly revenue was up 30.6% on a year-over-year basis. Axon Enterprise updated its Q4 2025 guidance to EPS and its FY 2025 guidance to EPS.

Axon Enterprise Price Performance

Shares of NASDAQ:AXON traded down $75.59 on Wednesday, hitting $630.54. The company’s stock had a trading volume of 3,157,367 shares, compared to its average volume of 680,632. The company has a 50-day simple moving average of $729.01 and a 200 day simple moving average of $736.07. Axon Enterprise has a 1 year low of $450.72 and a 1 year high of $885.91. The company has a market capitalization of $49.50 billion, a PE ratio of 155.69, a PEG ratio of 29.49 and a beta of 1.41. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.95 and a quick ratio of 2.71.

Insider Transactions at Axon Enterprise

In other Axon Enterprise news, CAO Jennifer H. Mak sold 77 shares of the firm’s stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $760.00, for a total value of $58,520.00. Following the sale, the chief accounting officer owned 15,003 shares of the company’s stock, valued at $11,402,280. This trade represents a 0.51% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, President Joshua Isner sold 15,919 shares of the firm’s stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $746.26, for a total value of $11,879,712.94. Following the completion of the sale, the president directly owned 238,379 shares in the company, valued at approximately $177,892,712.54. The trade was a 6.26% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 59,932 shares of company stock worth $45,115,616. 4.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Axon Enterprise

Several institutional investors have recently modified their holdings of the company. B. Riley Wealth Advisors Inc. bought a new position in shares of Axon Enterprise during the 2nd quarter valued at about $478,000. Advisory Services Network LLC increased its position in shares of Axon Enterprise by 207.3% during the 2nd quarter. Advisory Services Network LLC now owns 3,304 shares of the biotechnology company’s stock valued at $2,496,000 after purchasing an additional 2,229 shares during the last quarter. State of Wyoming bought a new position in shares of Axon Enterprise during the 2nd quarter valued at about $268,000. Evergreen Capital Management LLC increased its position in shares of Axon Enterprise by 3.8% during the 2nd quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock valued at $342,000 after purchasing an additional 15 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co increased its position in shares of Axon Enterprise by 26.9% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 86,503 shares of the biotechnology company’s stock valued at $71,688,000 after purchasing an additional 18,362 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Axon Enterprise in a research report on Wednesday, October 8th. Bank of America upped their price target on Axon Enterprise from $895.00 to $1,000.00 and gave the company a “buy” rating in a research report on Wednesday, August 6th. The Goldman Sachs Group dropped their price objective on Axon Enterprise from $940.00 to $800.00 and set a “buy” rating on the stock in a report on Wednesday. UBS Group reissued a “neutral” rating and set a $840.00 price objective (up previously from $820.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Finally, Craig Hallum raised Axon Enterprise from a “hold” rating to a “buy” rating and set a $900.00 price objective on the stock in a report on Tuesday, August 5th. Fourteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $829.50.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.